Endless Biotech is Revolutionizing Tissue Culture Cultivation
Learn more about Early-Stage Shares
Accredited investor?
Get early access.
Limited time opportunity for EARLY STAGE INVESTORS to join our Regulation D offering, featuring early-stage investment discounts—25% below market value for investments of $25,000+, and a 50% discount for investments $250,000+. In the coming weeks, we anticipate our Regulation A+ $1.00 public stock offering qualification, paving the way for broader investor access. With a path toward a NASDAQ IPO planned for 2028, this is your chance to get in early and grow with us at the forefront of the agricultural biotech revolution.
To invest, you must meet at least one of the SEC’s criteria:
Top Reasons to Invest in Endless Biotech
Visionary Growth
Pursuing a long-term strategy aimed at a future NASDAQ IPO and global expansion.
Fortune 100 Expertise
Led by seasoned executives with proven track records.
Early Stage Opportunity
Secure early-stage shares in a rapidly growing market.
Projected Global Cannabis Market by 2030
The global cannabis market is expected to hit $444 billion by 2030, fueled by legalization, innovation, and rising global demand.
SourceGlobal Agriculture Market by 2025
The global agriculture market is set to reach $15.5 trillion by 2025, driven by population growth, trade expansion, and tech innovation.
SourceMonthly Clone Production with Robotics & AI
Endless Biotech’s goal is to produce up to 5 million clones per month using robotics and AI—scaling agriculture with precision and consistency.
Strategic
Partners
Endless Biotech is poised to revolutionize agriculture by integrating cutting-edge biotechnology with sustainable practices, aiming to enhance crop yields and resilience.
Chief Revenue Officer
Robotics &
AI Automation
- Consistency
- Efficiency
- Scalability
- Sustainability
Subscription Driven Eco System
Our subscription-based service offers a complete ecosystem for cultivators, providing them with regular shipments of tissue culture clones, expert advice, and cutting-edge growth solutions.
This model ensures that growers receive a steady supply of high-quality plants while benefiting from ongoing support, cost predictability, and scalability options to match their growth needs.
Data-Driven Solutions
We harness the power of data analytics and scientific insights to optimize every stage of cultivation. By continuously monitoring and refining our tissue culture processes, we ensure that growers receive plants with superior genetics and performance.
This data-driven approach allows us to predict growth patterns, enhance plant health, and deliver results that align with the evolving needs of the agriculture industry, ensuring maximum success for our partners.
Global Distribution
Endless Biotech is committed to serving cultivators on a global scale. With distribution networks established both nationally and internationally, we are positioned to deliver premium tissue culture plants to cultivators worldwide.
Our distribution strategy focuses on providing seamless, efficient access to our products, ensuring that our partners can rely on a consistent supply wherever they are located.
Endless Campus
As we look toward the future, our planned Endless Campus represents the heart of our innovation and growth. This state-of-the-art facility will serve as a hub for research, production, and collaboration, enabling us to scale operations while maintaining the highest standards of quality. The campus is a testament to our commitment to leading the agriculture industry into the future.
Proof of Concept
Initial Expansion
Scaling Up
Global Growth
Come See it Grow
We invite potential investors to visit our campus in Tulsa, Oklahoma, and see where the future of precision cultivation is being built. Tours are available Monday through Friday by appointment.
“Endless is defying the laws of Crop Steering Methodology. Their ability to produce phenomenal yields and high quality products is a cornerstone to their success. They are making a name for themselves locally, nationally, and internationally. It will be fun to watch them grow over the next few years!”
Regional Sales
Roadmap to 2029
Endless Biotech’s vision extends beyond today, with a strategic roadmap designed to drive the company’s growth through 2029. Our timeline includes expanding production capacities, entering new markets, and introducing breakthrough innovations in tissue culture technology. Each milestone brings us closer to becoming a global leader in cannabis cultivation and tissue culture solutions.
First 5 Million Tissue Culture Clones Delivered
Endless successfully hit a major milestone by delivering 5 million tissue culture clones to indoor and outdoor grow operations across the U.S.
Global Distribution Network Launched
Endless Biotech's international distribution network now reaches key markets worldwide, allowing the rapid deployment of tissue culture clones to growers globally.
First 5 Million Tissue Culture Clones Delivered
Endless successfully hit a major milestone by delivering 5 million tissue culture clones to indoor and outdoor grow operations across the U.S.
First 5 Million Tissue Culture Clones Delivered
Endless successfully hit a major milestone by delivering 5 million tissue culture clones to indoor and outdoor grow operations across the U.S.
Endless Plants
Horticulture
Advanced horticultural genetics ensuring improved yield, resilience, and consistency in everyday staples.
Tree Species
Reliable, genetically optimized tree varieties for sustainable landscaping and agricultural applications.
Floriculture
Specialized floriculture genetics for vibrant and resilient blooms, including refined Orchids and robust Chrysanthemums (Mums).
Cannabis
Meticulously cultivated cannabis genetics engineered for optimal growth and unmatched potency.
Meet the Endless Biotech Team
Travis Dahm
A 15-year veteran of the financial and fintech industries, Travis has leveraged technology, entrepreneurial management, and client-focused strategies to scale companies into global enterprises.
Throughout his career, Travis has led international expansions across Asia, Europe, the Americas, and Australia, building multi-regional teams to support rapid growth. His expertise has helped businesses handle over $1 billion in payments annually, trillions in trade volume, and serve hundreds of thousands of clients.
Travis believes that a business thrives on strong teams and products. With a clear vision, the right team, and a superior product, success becomes a matter of seizing strategic opportunities and forming key partnerships.
David Hamilton
David Hamilton is a seasoned executive with a proven track record in scaling organizations and driving revenue growth across Fortune 100 and 500 companies, including HP, McKesson, and Philips Healthcare. Over his career, he has contributed to more than $250 billion in new revenue and brokered the largest tech deal in U.S. government history.
As a former CEO and current advisor to four Fortune 100s, David brings deep expertise across sales, operations, marketing, and investor relations. He’s known for leading transformative growth strategies grounded in trust, performance, and cross-functional integration.
David joins Endless Biotech with a bold vision: to help the company reshape the future of big agriculture and scale into a global market leader.
Tim Lozott
Leverages his experience as a vertical operator in the cannabis industry to position Endless Biotech as a global leader in tissue culture and clones. He joined the team to drive growth, scalability, and execute an exit strategy targeting a Nasdaq or NYSE listing by 2028.
Starting in corporate finance, Lozott managed REIT funds with $2–7 billion in real estate assets and holds expertise in finance, accounting, operations, and law. He transitioned into cannabis in 2018, leading a turnaround of a struggling pre-IPO company, increasing revenues, and orchestrating the $100 million sale of Acres Cannabis Las Vegas to Curaleaf.
Following this success, Lozott founded GreenLife Capital, a private equity firm that has raised over $300 million for cannabis and other ventures. He brings the experience needed to guide Endless Biotech to the public markets.
Braz Vaidya
Brajesh Vaidya is a pioneering figure in plant biotechnology, distinguished by his expertise in advancing tissue culture and plant propagation techniques that drive sustainable growth and commercial scalability in agriculture. With decades in the field, Braz has developed innovative protocols for creating disease-free plant stocks, critical in producing consistent, high-quality clones for commercial cultivation. His work emphasizes meticulous lab management, including developing and implementing SOPs that meet stringent regulatory standards, while optimizing efficiency for large-scale production environments.
Throughout his career, Braz has led teams in R&D, where his disciplined approach has facilitated substantial breakthroughs in plant tissue culture, viroid testing, and disease management. Braz excels in cross-functional collaboration, coordinating with both internal teams and external stakeholders to meet project timelines and deliver actionable insights that inform broader production strategies. Known for his ability to bridge scientific research with commercial application, he has helped build frameworks that streamline operations from pilot to full-scale production, making significant impacts on both national and international biotech initiatives.
Gary Holland
An engineer, director, and architect with extensive experience developing software for Fortune 500 companies and helping cannabis growers optimize operations. His blend of corporate insight and technical expertise allows him to craft effective solutions for complex challenges.
A U.S. Navy veteran, Gary served as a Nuclear Engineer on Ballistic Missile Submarines and developed a Nuclear Instrument Monitoring System still in use today. He also designed a patent-pending AI system modeled on human brain structures and contributed to NASA’s Next-Generation Shuttle Analysis Project.
Gary’s work in AI-based architectures has supported federal agencies and major corporations. His diverse education spans Computer Science, Astrophysics, Nuclear Engineering, and Electrical Engineering, giving him the tools to bridge cutting-edge technology with real-world business needs.
Courtney Bridges
Courtney Bridges is a scientist by day and an artist at heart, merging the precision of biology with the creativity of visual design. She earned a Bachelor of Science in Biology from the University of Maryland, where she focused on plant sciences and ecological systems. Alongside her scientific studies, she completed an Associate of Arts in Visual Design, giving her a unique ability to integrate analytical thinking with artistic expression.
Her career began at the USDA, where she gained invaluable experience in horticultural research, deepening her understanding of plant cultivation and environmental management. Simultaneously, her work in event space management refined her skills in operations, planning, and project coordination—abilities that would later support her entrepreneurial ventures.
Now, Courtney plays a key role in advancing horticultural research with Endless Biotech, applying her scientific expertise to explore innovative plant technologies. With a career rooted in science, design, and entrepreneurship, she continues to push boundaries in the medical plant industry.
“Endless Biotech is a cutting-edge, top-notch facility. Their team is dedicated, professional, and passionate, delivering exceptional data-driven results. If you want science-backed efficiency, Endless is the way to go.”
Regional Sales
What are the potential benefits of investing in Endless Biotech’s early-stage shares?
Investing in Endless Biotech’s early-stage shares offers unique advantages, including the opportunity to participate in the growth of a pioneering biotech company at a foundational stage. As the company’s innovations in tissue culture, genetics, and automation drive expansion and market reach, early investors could benefit from potential value increases over time. Additionally, Endless Biotech’s strategic goal to list on the Nasdaq by 2028 could further enhance share value, creating significant upside potential for early stakeholders.
What are the key milestones in Endless Biotech’s growth roadmap from 2024 to 2028?
Endless Biotech’s roadmap to 2028 includes several ambitious milestones. By the end of 2024, the company aims to complete its first SEC-qualified Reg A+ stock offering and establish initial fulfillment centers. By 2026, the plan is to open a 40,000-square-foot tissue culture lab, positioning it as a global leader in cannabis biotech. In 2028, Endless Biotech anticipates achieving a Nasdaq listing, which would solidify its standing in the agricultural biotech market. These milestones are designed to support robust growth, increase market penetration, and bring significant advancements to cannabis cultivation through technology and innovation.
How does Endless Biotech's subscription service for cultivators work, and what are its benefits?
Endless Biotech’s subscription service is tailored to meet the needs of cannabis cultivators by providing consistent access to high-quality tissue-culture-grown plants. Subscribers receive regular deliveries of pathogen-free clones and benefit from genetic stability across crops, reducing the risks associated with traditional propagation. This service helps cultivators achieve uniform yields, maintain crop quality, and meet regulatory standards more easily. With flexible delivery schedules and scalable options, the subscription model supports cultivators of all sizes, from boutique growers to large-scale commercial operations.
How does Endless Biotech plan to scale its tissue culture and cannabis genetics operations globally?
Endless Biotech is scaling its operations through a multi-phase expansion strategy that includes building state-of-the-art tissue culture facilities, establishing fulfillment centers on the East and West Coasts, and constructing the world’s largest cannabis tissue culture lab. By leveraging advanced robotics, artificial intelligence, and strategic international partnerships, the company aims to efficiently expand its reach to Northern Europe, Africa, and Asia. This approach not only facilitates global distribution but also enables localized support and faster access to markets around the world.
What is tissue culture, and why is it advantageous in cannabis cultivation?
Tissue culture is a cutting-edge propagation method that involves growing cannabis plants from a small sample of plant cells in a sterile, controlled environment. This process ensures that each plant produced is genetically identical to its parent, free from contaminants, pests, and diseases that can affect traditional clones or seeds. In cannabis cultivation, tissue culture allows for consistent quality, faster growth cycles, and improved yield predictability, making it an ideal solution for cultivators seeking uniformity and reliability across large-scale operations.
Can tissue culture plants serve both medical and recreational cannabis markets, and what are the benefits?
Yes, tissue culture plants can be utilized in both the medical and recreational cannabis markets. Tissue culture ensures a higher level of plant purity and consistency, making it ideal for medical cannabis where product quality and reliability are essential for patient safety. In the recreational market, the uniformity and resilience of tissue-culture-grown plants lead to high-quality, predictable experiences for consumers. This dual applicability makes tissue culture a versatile and beneficial method for cultivators looking to meet diverse market demands.
At Endless, we are combining data driven science, innovation using robotics and AI, and scale to deliver the next generation of cannabis cultivation. We’re not just growing plants—we’re building the future of agriculture. And with these existing and emerging technologies, the possibilities truly are Endless.
Chief Scientist, Head of Tissue Culture
Regulation A Tier 2 Stock Offering
- $1.00 per share
- Minimum 650 shares
- REG A+ "Regulation A" Stock Offering